cycloserine, pyrazinamide, and ethambutol. After 6-9 months of intensive phase, levofloxacin, ethionamide, ethambutol, and cycloserine were continued for 18 months. The baseline demographic characteristics of all the patients were recorded. The patients were categorized into predefined treatment outcomes. The cure was defined as a patient who has completed treatment and has at least five consecutive negative results in the past 12-15 months. In case of positivity in the last three-quarters, if the positive culture was followed by three negative cultures (at least 30 days apart), they were still considered as cured. The patients were categorized as treatment failure if two or more of the cultures turned out to be positive in the final 12-15 months or even one of the final three cultures were positive. In cases, where no bacteriological results were available, they were categorized into treatment completed after 24 months of treatment. Treatment default was considered to be the outcome if the treatment was interrupted for 2 or more months. The other outcomes that were defined according to the RNTCP guidelines were as follows: Death, Transfer out (to another DOTS-plus site) and switched to Category V treatment.
Data analysis
The frequency of different baseline characteristics and outcomes were expressed as a percentage. Their 95% confidence intervals (CIs) were calculated. The data were analyzed with Stata version 12.1 (StataCorp LLC, College Station, Texas, USA).
Results
A total of 819 patients were registered at our DOTS-plus site from 2009 to 2013. Of these, 329 patients (40.2%, 95% CI -36.9-43.6) were female and 490 patients (59.8%, 95% CI -56.4-63.1) were male. The mean age at the time of presentation was 30.6 years (standard deviation : 13 were nondiabetic. The frequency of predefined outcomes in these patients was as follows: cured (n = 415, 52%, 95% CI -47.2-54), default (n = 199, 24%, 95% CI -21.5-27.3), death (n = 130, 16%, 95% CI -13.5-18.5), switched to category V (n = 27, 3%, 95% CI -2.3-4.8), transferred out (n = 12, 1%, 95% CI -0.8-2.6), treatment failure (n = 13, 1%, 95% CI -0.9-2.7) [ Figure 4 ]. A total of only 23 patients (3%, 95% CI -1.9-4.2) were extra-pulmonary MDR-TB and so proof of cure could not be ascertained at the end of the treatment course. These patients were classified as treatment completed. 
dIscussIon
According to the Global tuberculosis report, 2013, the incidence of MDR-TB in new cases was 3.6% while that in retreatment cases was 20.2%. [1] A very high proportion of these MDR-TB cases were from India. The incidence of MDR-TB in India is around 1%-3% in newly diagnosed cases. [2, 3] In most studies from India and abroad, MDR-TB was more commonly seen in patients who had a history of previous treatment.
[ [4] [5] [6] In concordance with these studies, majority of our patients had received previous antitubercular treatment. Although base line immune status (HIV and diabetes) was recorded for most of the patients, it has been seen in systematic reviews that treatment outcomes are not significantly affected by them. [7] Successful treatment outcomes or cure in other Indian studies ranged from 33% to 61%. [8] [9] [10] [11] [12] The cure rate of MDR treatment from other parts of the world ranges from 44% to 77%. [13] [14] [15] [16] [17] The percentage of patients succumbing to death during treatment varies from 8% to 30% in Indian settings. [8] [9] [10] [11] [12] The percentage of defaulters in various Indian centers differs from 8% to 21%. [8] [9] [10] [11] [12] The failure rate in the patients on treatment ranges from 6% to 13% in the Indian subcontinent. [9] [10] [11] [12] As evident from our review, there was considerable variation in the treatment outcomes in different studies. It was found in a meta-analysis that the duration of treatment and whether the therapy was directly observed or not, was very important in determining the treatment outcomes. Furthermore, it was seen that individualized treatment regimens were slightly better than standardized treatment regimens. [18] The patients received long duration of directly observed therapy, but due to the lack of abundant laboratories with drug susceptibility testing capabilities, we still follow standardized treatment regimens under the national program. Most of the findings in our study were consistent with other published Indian studies. Even though our cure rate of 52% was comparable to the cure rates reported from other national and international studies, it is still far behind the current goals. We also had a very high percentage of patients who defaulted (24%) or died (16%) during treatment. The high percentage of failure rates in the treatment of MDR-TB is primarily due to the long duration of treatment and side effects associated with the second-line drugs. There is a lot of research going on toward the development of shorter, simpler, and alloral regimes. The STREAM trial Stage 1 has shown promising results. [19] WHO has given a conditional recommendation for short regimes but their applicability in Indian settings is a question for debate.
[20]
Limitation of the study
The retrospective study design was associated with its inherent limitations. The drug resistance pattern to other drugs and previous treatment history was not available for all the patients.
conclusIon
This study points out the menace of MDR-TB in a high burden country like India. Although, the national program has been somewhat successful in implementing the DOTS-plus strategy, the high death and default rates needs to be addressed further. Continued programmatic efforts are required to tackle the challenge that MDR-TB is.
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